Merck reported third-quarter revenue of $16.66 billion and adjusted earnings of $1.57 per share, surpassing analyst expectations. Strong sales from Keytruda and new treatments offset a decline in Gardasil vaccine sales, which fell 11% due to lower demand in China. The company narrowed its full-year sales forecast and adjusted profit guidance, reflecting a one-time charge related to business development deals.
gilead withdraws trodelvy from bladder cancer market after negative trial results
Gilead has withdrawn its bladder cancer treatment Trodelvy after a confirmatory study failed to demonstrate improved survival rates. Initially granted accelerated approval in 2021, the decision reflects the FDA's increased scrutiny of such approvals. Despite this setback, Trodelvy remains a key player in Gilead's oncology portfolio, particularly for breast cancer, where sales are projected to reach $1 billion by 2030.
Nikkei rises on tech gains while investors await corporate results
The SMI closed lower, with Swiss Re among the decliners, while Wall Street showed weakness. In Tokyo, the Nikkei index rose 0.3% to 39,110.95, buoyed by technology stocks like Advantest and Tokyo Electron, despite caution ahead of corporate results and the upcoming general election on October 27. Fast Retailing, KDDI, and Daiichi Sankyo were among the notable losers.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.